Trials & Tribulations What NHS-Galleri taught us—and what it didn’t June 18, 2026Vol.52 No.24By Scott D. Ramsey and Ruth Etzioni
Trials & Tribulations The NHS-Galleri trial has and will continue to provide critical insights to refine future MCED studies June 18, 2026Vol.52 No.24By Bryan Bassig, Catherine R. Marinac, David M. Routman, Elizabeth K. O'Donnell, Jennifer Keating Litton, Karthik V. Giridhar, Kennedy Ng Yao Yi, Kurt Giles, Nima Nabavizadeh, Ora K. Gordon, Rebecca Kaltman and Shawn Kothari
FreeTrials & Tribulations Lessons from the AIDS Quilt: what the cancer world can learn from AIDS advocacy June 12, 2026Vol.52 No.23By Peter F. Garrett
Pancreatic cancer finally starts to budge as daraxonrasib doubles overall survival June 05, 2026Vol.52 No.22By Jacquelyn Cobb
Trials & Tribulations The story of daraxonrasib is the ultimate hero’s journeyA narrative curve with twists, turns, intrigue, drama—and a blow to a mighty foe June 05, 2026Vol.52 No.22By W. Kimryn Rathmell
When CAM is added to standard therapies, survival rates drop, observational study finds May 29, 2026Vol.52 No.21By Jacquelyn Cobb
Trials & Tribulations As rural cancer disparities persist, aligning policy with care delivery models can close the gap May 29, 2026Vol.52 No.21By Matthew L. Anderson
FDA clears fruit-flavored vapes, relaxes enforcement on black-market products with pending premarket applicationsCritics say policies clear the way for major tobacco companies to enter fruit-flavored vape market May 15, 2026Vol.52 No.19By Sara Willa Ernst
Problem: Misinformation and stigma prevent uptake of HPV vaccines and screening. Solution: A comic book April 24, 2026Vol.52 No.16By Jacquelyn Cobb
Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OSPanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.” April 17, 2026Vol.52 No.15By Jacquelyn Cobb
